Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback